Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Acurx Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

THE OBJECTIVE OF THIS NEW PHASE OF COLLABORATION WITH LEIDEN UNIVERSITY MEDICAL CENTER (LUMC) IS TO FURTHER ADVANCE THE RECENTLY COMPLETED AND PUBLISHED PIONEERING RESEARCH TO DETERMINE WHETHER THE MODES OF DNA POLYMERASE POL IIIC (POLC) ACTION AND RESISTANCE ARE CONSERVED ACROSS IMPORTANT SPECIES OF GRAM-POSITIVE MULTIDRUG RESISTANT ORGANISMS THE PREVIOUS LUMC-ACURX HEALTH~HOLLAND PROJECT SUCCESSFULLY ELUCIDATED THE STRUCTURE OF POLC FROM E. FAECIUM, A CRITICAL GRAM-POSITIVE HUMAN PATHOGEN, IN COMPLEX WITH TWO ACURX POL IIIC INHIBITORS.

HEALTH~HOLLAND AWARDS ANOTHER INNOVATIVE RESEARCH GRANT FOR DNA POL IIIC INHIBITORS TO LEIDEN UNIVERSITY MEDICAL CENTER AND ACURX PHARMACEUTICALS

STATEN ISLAND, N.Y. , NOV. 12, 2025 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY CERTAIN FINANCIAL AND OPERATIONAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

ACURX PHARMACEUTICALS, INC. REPORTS THIRD QUARTER RESULTS AND PROVIDES BUSINESS UPDATE

DNA POLYMERASE (POL) IIIC INHIBITORS ARE AN INNOVATIVE NEW CLASS OF ANTIBIOTICS, THE FIRST IN MORE THAN 30 YEARS, THAT TARGET A CRITICAL ENZYME OF GRAM-POSITIVE BACTERIA INCLUDINGC. DIFFICILE, MRSA, VRE AND PRSP (PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIA) ACURX'S LEAD DNA POL IIIC ANTIBIOTIC, IBEZAPOLSTAT (IBZ), HAS CLINICALLY VALIDATED THIS BACTERIAL TARGET BY DEMONSTRATING PHASE 2 EFFICACY IN THE TREATMENT OF C.

ACURX ANNOUNCES PUBLICATION IN THE NATURE COMMUNICATIONS SCIENTIFIC JOURNAL DOCUMENTING ITS UNIQUE TARGETING OF DNA POL IIIC GRAM-POSITIVE PRIORITY PATHOGENS

PIONEERING DATA DEMONSTRATE THATACURX'S U.S. AND EU PHASE 3-READY DNA POL IIIC INHIBITOR, IBEZAPOLSTAT (IBZ), HAS UNIQUE SELECTIVE ANTIBACTERIAL ACTIVITY IN THE GUT WHICH SPARES BENEFICIAL BILE ACID-METABOLIZING BACTERIA THE FAVORABLE GUT BILE ACID PROFILE CONTRIBUTES TOIBEZAPOLSTAT'SANTI-RECURRENCEEFFECTINPATIENTSWITHC.DIFFICILEINFECTION(CDI) NEW DATA PRESENTED ON REPRESENTATIVE NOVEL COMPOUNDS FROMACURX'S DNA POL IIIC INHIBITOR PRECLINICAL PIPELINE PROVIDE INITIAL EVIDENCE THAT MICROBIOME SELECTIVITY, WHEN COMPARED TO THE COMPARATOR ANTIBIOTIC, LINEZOLID, MAY BE A CLASS EFFECT IBEZAPOLSTAT HAS PREVIOUSLY RECEIVED FDA QIDP AND FAST-TRACK DESIGNATION FROM FDA; ACURX'S PRECLINICAL ANTIBIOTIC CANDIDATES ARE FDA QIDP/FAST TRACK ELIGIBLE FOR SYSTEMIC TREATMENT OF INFECTIONS CAUSED BY OTHER GRAM-POSITIVE PRIORITY PATHOGENS STATEN ISLAND, N.Y.

ACURX ANNOUNCES NEW DATA ON ITS DNA POL IIIC INHIBITOR ANTIBIOTICS DEMONSTRATING A POTENTIAL CLASS EFFECT OF GUT MICROBIOME SELECTIVITY PRESENTED AT IDWEEK 2025 SCIENTIFIC CONFERENCE

STATEN ISLAND, N.Y. , OCT. 27, 2025 /PRNEWSWIRE/ -- ACURX PHARMACEUTICALS, INC. (NASDAQ: ACXP) ("ACURX" OR THE "COMPANY"), A LATE-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A NEW CLASS OF ANTIBIOTICS FOR DIFFICULT-TO-TREAT BACTERIAL INFECTIONS, ANNOUNCED TODAY THAT THE COMPANY WILL DISCUSS ITS THIRD QUARTER 2025 FINANCIAL RESULTS ON WEDNESDAY, NOVEMBER 12, 2025 AT 8:00 AM ET BEFORE THE U.S. FINANCIAL MARKETS OPEN.

Acurx Pharmaceuticals, Inc.

ACXP

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Acurx Pharmaceuticals, Inc.

ACXP.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ACXP